CeriBell, Inc.
CBLL · Price history
Price at last available close
$27.80
+$2.94 (+11.82%) 1M
2026-10-29
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About CeriBell, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
CeriBell, Inc. specializes in pioneering artificial intelligence (AI)-powered electroencephalography (EEG) solutions designed for the immediate diagnosis and treatment of neurological conditions directly at the patient's bedside. The company's primary offering is the Ceribell System, an innovative, on-site EEG platform engineered to fulfill crucial, previously unmet requirements for patients in urgent medical environments. Beyond the core system, CeriBell also provides single-use EEG headbands and compact, battery-powered recording devices.
How they make money
Ceribell generates revenue primarily through the sale of disposable wearable EEG headbands and recurring monthly subscription fees for access to its cloud-based portal, seizure detection algorithms, and recording hardware. The company operates a razor-and-blade business model where the initial deployment of the Ceribell System hardware facilitates ongoing, recurring usage-based revenue from disposables and software services in acute-care hospital settings.
Products & services
The Ceribell System is a point-of-care electroencephalography (EEG) platform that combines portable hardware with AI-powered algorithms for rapid seizure detection and continuous neurological monitoring.
Brands & revenue mix
The primary point-of-care EEG platform and associated disposable components.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
Customer concentration
The company does not disclose specific customer concentration figures in its 2025 annual report.
Suppliers, materials & equipment
- Contract Manufacturers — The company relies on third-party contract manufacturers for the production of its hardware components and disposable headbands; specific supplier names are not disclosed.Source
Strengths
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
26
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
39
Poor
Financial Strength
32
Business Quality / Moat
50
Management
40
Growth Quality
45
Risk / Durability
23
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
36
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
49/100
Building Historical Record
Model Score 49/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
No strong positive signal is being highlighted from the currently available summary data.
- •Debt service risk
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Debt / balance-sheet profile needs attention
- •Asset quality is a weaker factor
Company-specific research
Questions worth answering for CBLL
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can CBLL maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •How long can CBLL fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •Does CBLL's balance between cash and debt leave enough flexibility if business conditions weaken?
- •What specifically needs to improve for CBLL to reach sustainable profitability?
- •What future growth or profitability would be needed to justify CBLL's current valuation?
Essential Investment Snapshot
Wall Street Score
26
Opportunity Score
36
Market Cap
$1.07B
P/E Ratio
-13.9
EPS
$-1.76
52-Week High
$25.63
52-Week Low
$10.85
Beta
0.81
Analyst Target
$27.50
Shares Outstanding
36.5M
Total Revenue
$102.0M
Total Debt
$21.9M
Dividend
No current dividend
Liquidation Value / Share
$3.51
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong upward momentum
Elevated movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for CBLL
Detected from reported data — verify before acting.Debt service risk
Interest coverage is low (~-30.9x). Earnings may be strained to cover interest expense.
Community Sentiment
0 active · 0 total callsNo personal call yet on CBLL.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary AI-powered seizure detection algorithms.
- +Rapidly deployable and portable hardware design.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Medical - Devices industry.
- −Dependence on sales from the use of the Ceribell System.
- −Reliance on third-party manufacturers for production.
- −Negative free cash flow may increase the need for outside financing and dilution.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
5 historical score records availablePrevious Score
26
Sep 14, 2026
Change
Unchanged
Current Score
26
Oct 1, 2026
Category Changes
CBLL score was unchanged.
Projected Score
Projected Score
32
Projected Change
+5.6 points
Preliminary comparable-period financial changes suggest improvement of approximately 5.6 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
Valuation unavailableCurrent Price
$27.81
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | $102.0M | $89.1M | $65.4M | $45.2M | ···· |
| Cost of Revenue | $11.3M | $10.8M | $8.7M | $7.1M | ···· |
| Gross Profit | $90.6M | $78.3M | $56.8M | $38.2M | ···· |
| Research & Development | $23.0M | $19.1M | $13.6M | $9.0M | ···· |
| SG&A Expenses | $137.7M | $117.5M | $82.9M | $59.2M | ···· |
| Operating Expenses | $160.6M | $136.7M | $96.5M | $68.2M | ···· |
| EBITDA | -$63.1M | -$50.2M | -$37.3M | -$26.5M | ···· |
| Operating Income | -$70.0M | -$58.4M | -$39.7M | -$30.0M | ···· |
| Interest Expense | $1.8M | $1.9M | $2.0M | $2.1M | ···· |
| Income Before Tax | -$66.0M | -$53.4M | -$40.5M | -$29.5M | ···· |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $11K | ···· |
| Net Income | -$66.0M | -$53.4M | -$40.5M | -$29.5M | ···· |
| Basic EPS | $-1.76 | $-1.46 | $-1.13 | $-1.26 | ···· |
| Basic Shares | 38.03M | 36.54M | 35.85M | 23.32M | ···· |
| Diluted Shares | 38.03M | 36.54M | 35.85M | 23.32M | ···· |
Earnings Summary
Revenue
$28.1M
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$0.51
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
+1.7%
Cash Change
-18.6%
Margin Change
-4.2 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Weakened
- Margins contracted
- Cash position declined
- Debt increased
Potential Score Impact
Positive indicators included revenue growth, EPS growth. Pressure indicators included cash levels, debt levels, net income margin. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 32.5%. EPS increased 34.2%. Cash declined 18.6%. Total debt increased 1.7%. Net income margin declined by 4.2 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
5 historical recordsHistorical Score Chart
3 of 5 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Medical - DevicesNews
Ceribell Receives FDA 510(k) Clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis
BlackRock Inc. Acquires New Holdings in CeriBell, Inc. $CBLL
Bank of America Corp DE Has $5.86 Million Position in CeriBell, Inc. $CBLL
CeriBell Expands EEG Platform Beyond Seizures With Delirium, Pediatric Push
Rumor Mill · CBLL
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial